Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome.
Uta M Demel, Anna Meurer, Badeel Kh Q Zaghla, Bilge Atay, Daniel Steiert, Luca V Hummel, Konstandina Isaakidis, Chuanbing Zang, Michael Korenkov, Marlon Schielin, Schayan Yousefian, Shima Mecklenbräuker, Marieluise Kirchner, Simon Haas, Antonia Busse
Published: 202610.1002/advs.202511449
Abstract
A balanced SUMOylation equilibrium safeguards the functional anti-tumor immune response. Oncogene activation drives SUMOylation, rendering aberrant SUMOylation a hallmark of cancer. To delineate the impact of activated SUMOylation on the tumor-immune…
Preview only. Read the full abstract at the source